Sökning: id:"swepub:oai:DiVA.org:uu-524282" >
Uptake of doublet t...
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer : a population-based drug utilisation study in Sweden
-
- Gedeborg, Rolf (författare)
- Uppsala universitet,Anestesiologi och intensivvård,Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
-
- Sandin, Fredrik (författare)
- Uppsala Univ Hosp, Reg Canc Ctr, Uppsala, Sweden.,Regional Cancer Centre, Uppsala University Hospital, Uppsala, Sweden
-
- Thellenberg-Karlsson, Camilla, 1972- (författare)
- Umeå universitet,Onkologi,Umeå Univ, Dept Radiat Sci, Oncol, Umeå, Sweden.
-
visa fler...
-
- Styrke, Johan (författare)
- Umeå universitet,Urologi och andrologi,Umeå Univ, Dept Surg & Perioperat Sci Urol & Androl, Umeå, Sweden.
-
- Franck-Lissbrant, Ingela, 1969 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Univ Gothenburg, Dept Oncol, Inst Clin Sci, Sahlgrenska Acad, Gothenburg, Sweden.
-
- Garmo, Hans (författare)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper,Guys Hosp, Kings Coll London, Translat Oncol & Urol Res TOUR, London, England.,Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Translational Oncology and Urology Research (TOUR), King's College London, Guy's Hospital, London, United Kingdom
-
- Stattin, Pär (författare)
- Uppsala universitet,Urologkirurgi,Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
-
visa färre...
-
(creator_code:org_t)
- Medical Journals Sweden, 2023
- 2023
- Engelska.
-
Ingår i: Scandinavian journal of urology. - : Medical Journals Sweden. - 2168-1805 .- 2168-1813. ; 58, s. 93-100
- Relaterad länk:
-
https://doi.org/10.2...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://umu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
https://urn.kb.se/re...
-
https://gup.ub.gu.se...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Randomised controlled trials have demonstrated prolonged survival with new upfront treatments in addition to standard androgen deprivation therapy (ADT) in men with de novo metastatic castration-sensitive prostate cancer. We describe patient characteristics, time trends and regional differences in uptake of these new treatment strategies in clinical practice.Material and methods: This descriptive study consisted of men registered in the National Prostate Cancer Register of Sweden from 1 January 2018 to 31 March 2022 with de novo metastatic castration-sensitive prostate cancer defined by the presence of metastases on imaging at the time of diagnosis. Life expectancy was calculated based on age, Charlson Comorbidity Index and a Drug Comorbidity Index.Results: Within 6 months from diagnosis, 57% (1,677/2,959) of men with de novo metastatic castration-sensitive prostate cancer and more than 3 years of life expectancy had received docetaxel, abiraterone, enzalutamide, apalutamide and/or radiotherapy. Over time, there was a 2-fold increase in uptake of any added treatment, mainly driven by a 6-fold increase in use of abiraterone, enzalutamide or apalutamide, with little change in use of other treatments.Conclusions: Slightly more than half of men diagnosed with de novo metastatic castration-sensitive prostate cancer and a life expectancy of at least 3 years received additions to standard ADT as recommended by national guidelines in 2019-2022 in Sweden. There was a 2-fold increase in use of these treatments during the study period; however, efforts to further increase adherence to guidelines are warranted.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Nyckelord
- Prostate cancer
- castration sensitive prostate cancer
- abiraterone
- enzalutamide
- apalutamide
- docetaxel
- radiotherapy
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas